Healthy
Conditions
Keywords
metabotropic glutamate receptors 2 and 3, antagonist, mGluR, ketamine, BDNF, Depression, Major Depressive Disorder, Treatment Resistant Depression, Mood Disorder, Phase 1 safety, tolerability and pharmacokinetics study
Brief summary
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BCI-838 and its metabolite BCI-632 in healthy male and female subjects.
Detailed description
This study will evaluate the safety and tolerability following oral administration of multiple doses of BCI-838 in healthy male and female subjects. The pharmacokinetic profile of multiple oral doses of BCI-838 in healthy male and female subjects will also be assessed. In addition, the pharmacodynamic effects of BCI-838 on the central nervous system using quantitative electroencephalogram analysis will be studied.
Interventions
DRUGBCI-838
BCI-838 100 mg or matching placebo administered once daily for 7 days
Sponsors
BrainCells Inc.
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Adult male and female healthy volunteers, 18-55 years of age * Body Mass Index (BMI) between 18.0 to 30.0 kg/m2 inclusive * Female subjects must have a negative pregnancy test at screening and admission. Females of childbearing potential (not at least 2 years postmenopausal or surgically sterile) must be using a reliable, medically acceptable form of contraception for at least 30 days prior to the screening visit and must agree to continue such use throughout the duration of the study and for 3 months after the final dose of study drug. * Good general health as determined by medical history and physical examination with no clinically significant medical findings and no clinically relevant medical or surgical history and no acute or ongoing conditions within the past 30 days * Able to participate and willing to give written informed consent and to comply with the study restrictions
Exclusion criteria
* Clinically significant medical abnormality, chronic disease or history or presence of significant pulmonary, gastrointestinal, metabolic, cardiac, hepatic, renal or neurological disorder * History or current use of alcohol abuse or drug addiction * Participation in a drug study within 60 days prior to drug administration. * Participation in more than 3 other drug studies in the 10 months preceding the start of this study * Donation or blood loss of more than 50 mL of blood within 60 days prior to the first drug administration. Donation of more than 1.5 liters of blood in the 10 months preceding the start of this study * Illness within 5 days prior to drug administration
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety | 14 days | Safety will be evaluated by adverse events, vital signs, ECG, clinical labs, and physical exam. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cmax, tmax, t1/2 , AUC, CL/F, Vz/F, and Kel of BCI-838 and BCI-632 | predose, at specified timepoints during the 7-day dosing period, and at Day 10 (72 hours post-dose) | The pharmacokinetics of BCI-838 and its metabolite BCI-632 will be completed by assessment of Cmax, tmax, t1/2 , AUC, CL/F, Vz/F, and Kel. |
| Quantitative EEG (qEEG) assessments | predose, and at specified timepoints during the 7-day dosing period | The pharmacodynamic effects of BCI-838 on the central nervous system will be evaluated using quantitative electroencephalogram analysis. |
Countries
Netherlands
Outcome results
None listed